Gardasil 9

Country: Norveġja

Lingwa: Norveġiż

Sors: Statens legemiddelverk

Ingredjent attiv:

Humant papillomavirus, type 6 L1 protein, rekombinant / Humant papillomavirus, type 11 L1 protein, rekombinant / Humant papillomavirus, type 16 L1 protein, rekombinant / Humant papillomavirus, type 18 L1 protein, rekombinant / Humant papillomavirus, type 31 L1 protein, rekombinant / Humant papillomavirus, type 33 L1 protein, rekombinant / Humant papillomavirus, type 45 L1 protein, rekombinant / Humant papillomavirus, type 52 L1 protein, rekombinant / Humant papillomavirus, type 58 L1 protein, rekombinant

Disponibbli minn:

Orifarm AS

Kodiċi ATC:

J07BM03

INN (Isem Internazzjonali):

Humant papillomavirus, type 6 L1 protein, rekombinant / Humant papillomavirus, type 11 L1 protein, rekombinant / Humant papillomavirus, type 16 L1 protein, rekombinant / Humant papillomavirus, type 18 L1 protein, rekombinant / Humant papillomavirus, type 31 L1 protein, rekombinant / Humant papillomavirus, type 33 L1 protein, rekombinant / Humant papillomavirus, type 45 L1 protein, rekombinant / Humant papillomavirus, type 52 L1 protein, rekombinant / Humant papillomavirus, type 58 L1 protein, rekombinant

Għamla farmaċewtika:

Injeksjonsvæske, suspensjon

Unitajiet fil-pakkett:

Ferdigfylt sprøyte 1x0.5 ml

Tip ta 'preskrizzjoni:

C

L-istatus ta 'awtorizzazzjoni:

Markedsført

Data ta 'l-awtorizzazzjoni:

2022-04-01